C4 Therapeutics, Inc. SEC filings CCCC
C4 Therapeutics, Inc. has 546 filings in SEC EDGAR's recent list, going back to Jan 11, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Apr 29, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 10, 2025 | — |
| CORRESP | Letter to the SEC | Dec 8, 2025 | — |
| EFFECT | Filing | Nov 13, 2024 | — |
| EFFECT | Filing | Nov 13, 2024 | — |
| SUPPL | Filing | Nov 13, 2024 | — |
| SUPPL | Filing | Nov 13, 2024 | — |
| CORRESP | Letter to the SEC | Nov 8, 2024 | — |
| CORRESP | Letter to the SEC | Nov 8, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| EFFECT | Filing | May 3, 2023 | — |
| POSASR | Filing | Feb 23, 2023 | — |
| EFFECT | Filing | Jun 16, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| UPLOAD | Letter from the SEC | May 21, 2021 | — |
| DRS | Filing | May 19, 2021 | — |
| EFFECT | Filing | Oct 1, 2020 | — |
| CERT | Filing | Oct 1, 2020 | — |
| CORRESP | Letter to the SEC | Sep 29, 2020 | — |
| CORRESP | Letter to the SEC | Sep 29, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 28, 2020 | — |
| 8-A12B | Filing | Sep 28, 2020 | — |
| CORRESP | Letter to the SEC | Sep 15, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 11, 2020 | — |
| CORRESP | Letter to the SEC | Sep 10, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2020 | — |
| DRS | Filing | Aug 6, 2020 | — |
| D | Filing | Jan 11, 2016 | — |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CCCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662579
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.